Moderna Shifts Vaccine Funding Approach And Expands mRNA Oncology Ambitions

Simply Wall St.01-29

Moderna (NasdaqGS:MRNA) plans to stop funding new Phase III vaccine trials in the U.S., citing a more hostile vaccine climate. The company aims to secure external partners and funding for late stage ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2607081588?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/128680956-main-header/1756229826628","is_english":true,"pubTime":"2026-01-29 16:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607081588","market":"us","top_or_hot":-1,"title":"Moderna Shifts Vaccine Funding Approach And Expands mRNA Oncology Ambitions","media":"Simply Wall St.","content":"<div>\n<p>Moderna (NasdaqGS:MRNA) plans to stop funding new Phase III vaccine trials in the U.S., citing a more hostile vaccine climate. The company aims to secure external partners and funding for late stage ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/moderna-shifts-vaccine-funding-approach-and-expands-mrna-onc\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Shifts Vaccine Funding Approach And Expands mRNA Oncology Ambitions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Shifts Vaccine Funding Approach And Expands mRNA Oncology Ambitions\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-29 16:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/moderna-shifts-vaccine-funding-approach-and-expands-mrna-onc><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna (NasdaqGS:MRNA) plans to stop funding new Phase III vaccine trials in the U.S., citing a more hostile vaccine climate. The company aims to secure external partners and funding for late stage ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/moderna-shifts-vaccine-funding-approach-and-expands-mrna-onc\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/moderna-shifts-vaccine-funding-approach-and-expands-mrna-onc","article_id":"2607081588","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/128680956-main-header/1756229826628"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/moderna-shifts-vaccine-funding-approach-and-expands-mrna-onc","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2607081588","pubTimestamp":1769675336,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Moderna (NasdaqGS:MRNA) plans to stop funding new Phase III vaccine trials in the U.S., citing a more hostile vaccine climate.\nThe company aims to secure external partners and funding for late stage vaccine studies instead of relying solely on its own balance sheet.\nManagement is widening the focus of its mRNA platform beyond COVID 19 vaccines into cancer immunotherapy and other disease areas, including rare conditions.\n\nModerna, best known for its COVID 19 vaccine, is rethinking how and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK4548":"巴美列捷福持仓","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4501":"段永平概念","BK4551":"寇图资本持仓","MRNA":"Moderna, Inc.","BK4568":"美国抗疫概念","BK4588":"碎股"},"translate_title":"Moderna改变疫苗资助方式并扩大mRNA肿瘤学雄心","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"Moderna (NasdaqGS:MRNA) plans to stop funding new Phase III vaccine trials in the U.S., citing a more hostile vaccine climate. The company aims to secure external partners and funding for late stage vaccine studies instead of relying solely on its own balance sheet. Management is widening the focus of its mRNA platform beyond COVID 19 vaccines into cancer immunotherapy and other disease areas, including rare conditions.  Moderna, best known for its COVID 19 vaccine, is rethinking how and where it backs large, late stage vaccine programs. Recent CEO comments highlight a tougher backdrop for vaccines in the U.S., including shifting public sentiment and regulatory discussions that affect trial costs and timelines. For investors, an important question is how this change in approach affects capital needs, risk sharing and potential product mix over time. At the same time, Moderna is increasing its focus on mRNA applications in oncology and other diseases. This could change its revenue balance away from pandemic era products. The search for external partners on Phase III work also points to potentially more collaboration driven growth, where Moderna contributes the mRNA platform and other parties share trial and commercialization responsibilities. Stay updated on the most important news stories for Moderna by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Moderna. NasdaqGS:MRNA Earnings & Revenue Growth as at Jan 2026 How Moderna stacks up against its biggest competitors Moderna’s decision to stop self funding new Phase III vaccine trials in the U.S. and lean on partners looks like an attempt to conserve cash and share late stage risk while the business shifts away from its pandemic heavy profile. Moving more capital and attention toward mRNA cancer immunotherapy and other non respiratory diseases could gradually reposition the company closer to peers such as BioNTech and Merck, which are also pushing into oncology, while it continues to compete with vaccine players such as Pfizer in infectious diseases. AdvertisementHow this fits the Moderna narrative investors are already watching This pivot aligns with the existing narrative that long term progress in oncology and a broader mRNA pipeline will be important as COVID 19 revenue and margins come under pressure. It also sits against a mixed sentiment backdrop, where some analysts have turned more cautious and options activity has included sizeable put positions, while other analysts maintain relatively constructive views on the company’s earnings potential and pipeline breadth. Risks and rewards investors may want to weigh  ⚠️ Relying on external partners for late stage trials could slow timelines or reduce Moderna’s share of future economics if counterparties demand strong terms. ⚠️ A tougher vaccine climate in the U.S. and analyst expectations for an 8% EPS decline and 31.3% revenue drop for the upcoming period underline execution risk during this shift. 🎁 A 45.67% stock price gain over the past month and work on 35 mRNA candidates across multiple disease areas show that investors are already reacting to perceived pipeline potential. 🎁 Diversifying into cancer and rare diseases may reduce reliance on seasonal respiratory vaccines and could create more balanced revenue drivers over time if programs progress successfully.  What to watch from here From here, key things to watch include whether Moderna secures attractive partnership structures for its late stage vaccines, how quickly oncology programs move through the clinic, and what management says about cash use and trial funding on the upcoming February earnings call. For a broader sense of how different investors are thinking about these developments, you can review community narratives on Moderna’s stock page and compare those views with your own assumptions.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2607081588","isCrawlerRequest":true}